CompletedNCT03669250
Official study titleA Placebo-Controlled Study to Evaluate the Effect of a Single Dose of CVN058 on Mismatch Negativity in Subjects With Stable Schizophrenia
This study has finished and is no longer accepting participants.
In New YorkSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- Cerevance Alpha, Inc.
CompletedNCT02156908
Official study titleD-serine and Cognitive Remediation in Schizophrenia: Open Label Pilot
This study has finished and is no longer accepting participants.
In OrangeburgSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Nathan Kline Institute for Psychiatric Research
SuspendedNCT05046353
Official study titleD-serine Augmentation of Neuroplasticity-based Auditory Learning in Schizophrenia: R33 Phase
Recruitment is currently suspended.
In New YorkSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- New York State Psychiatric Institute
CompletedNCT03711500
Official study titleD-serine Augmentation of Neuroplasticity Based Auditory Learning in Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including New YorkSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- New York State Psychiatric Institute
CompletedNCT01390376
This study has finished and is no longer accepting participants.
In TaichungSchizophreniaMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- China Medical University Hospital
CompletedNCT02532686
This study has finished and is no longer accepting participants.
In TaichungSchizophreniaMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- China Medical University Hospital
TerminatedNCT01712646
Official study titleThe Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial
This study ended early.
In BethesdaSchizophreniaMedication studyAges 10–99
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)
CompletedNCT01041274
Official study titleCitalopram in First Episode Schizophrenia
This study has finished and is no longer accepting participants.
In New YorkSchizophrenia, DepressionMedication studyAges 16–40
- Countries
- United States
- Sponsor
- NYU Langone Health
CompletedNCT02187835
Official study titleDecreased EEG Complexity in Chronic Residual Schizophrenia
This study has finished and is no longer accepting participants.
In IstanbulSchizophreniaObservational studyAges 18–65
- Countries
- Türkiye
- Sponsor
- Uskudar University
WithdrawnNCT01725334
Official study titleDeep Brain Stimulation for the Management of Treatment Refractory Negative Symptoms in Schizophrenia
This study was withdrawn before enrollment.
In TorontoSchizophreniaInterventional studyAges 25–60
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT01689389
Official study titleDescription of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
This study has finished and is no longer accepting participants.
Multiple locations, including ArgenteuilSchizophrenia, BipolarityObservational studyAges 18–130
- Countries
- France
- Sponsor
- AstraZeneca
CompletedNCT04754750
Official study titleDifferences in Lipid and Cognitive Change Between One-month and 3-month Paliperidone Palmitate Treatment in Stable Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 30–69
- Countries
- Sponsor
- Calo Psychiatric Center